No Data
No Data
GTJA: Continuous iteration of anti-tumor therapies, domestic new drugs welcome breakthroughs.
GTJA focuses on products with significant differentiation advantages and leading companies in innovative segments.
Jiangsu Lianhuan Pharmaceutical Nixes Up to 300-Million-Yuan Share Issuance
Jiangsu Lianhuan Pharmaceutical: After nearly 0.3 billion failed placement, plans to borrow 0.2 billion from Banks for Innovative Drugs project "waiting for rice to cook" | Quick read announcement.
① Following the termination of the fundraising plan through the issuance of Convertible Bonds last year, Jiangsu Lianhuan Pharmaceutical has announced the termination of the plan to raise funds by issuing Stocks to specific targets through a simplified procedure. ② In order to develop Innovative Drugs projects, Jiangsu Lianhuan Pharmaceutical intends to apply for a research and development loan from the Jiangsu branch of the National Development Bank, with a credit amount of 0.24 billion yuan.
Jiangsu Lianhuan Pharmaceutical (600513.SH): Terminated the issuance of Stocks to specific targets for the 2024 fiscal year through a simplified procedure.
On February 24, Gelonghui reported that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that since the company announced the issuance of Stocks to specific targets through a simplified procedure for the year 2024, the company's Board of Directors, management, and intermediary organizations have been actively promoting various tasks. Considering the current market situation, along with the company's actual situation and development plan as well as many other factors, in order to protect the interests of the company and all Shareholders, after thorough communication and careful analysis with relevant parties, the decision was made to terminate the related matters concerning the issuance of Stocks to specific targets through a simplified procedure for the year 2024.
Lianhuan Pharma's Hypertension Drug Gets Registration Certificate
Jiangsu Lianhuan Pharmaceutical (600513.SH): Ainitial phase of Oseltamivir with Amlodipine tablets has obtained the Pharmaceutical Registration Certificate.
Gelonghui reported on February 7 that Jiangsu Lianhuan Pharmaceutical (600513.SH) announced that it recently received the "Drug Registration Certificate" approved by the National Medical Products Administration. The name of the pharmaceutical is Amlodipine Besilate and Olmesartan Medoxomil Tablets. This medication can be used to treat primary hypertension. This fixed-dose combination is suitable for adult patients who have poor blood pressure control with either Olmesartan Medoxomil or Amlodipine alone.
Why Jiangsu Lianhuan Pharmaceutical's (SHSE:600513) Shaky Earnings Are Just The Beginning Of Its Problems
